IBDEI0IW ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8503,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,8504,0)
;;=C92.00^^39^401^8
;;^UTILITY(U,$J,358.3,8504,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8504,1,3,0)
;;=3^Acute Myeloblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,8504,1,4,0)
;;=4^C92.00
;;^UTILITY(U,$J,358.3,8504,2)
;;=^5001789
;;^UTILITY(U,$J,358.3,8505,0)
;;=C92.61^^39^401^9
;;^UTILITY(U,$J,358.3,8505,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8505,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
;;^UTILITY(U,$J,358.3,8505,1,4,0)
;;=4^C92.61
;;^UTILITY(U,$J,358.3,8505,2)
;;=^5001808
;;^UTILITY(U,$J,358.3,8506,0)
;;=C92.60^^39^401^10
;;^UTILITY(U,$J,358.3,8506,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8506,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
;;^UTILITY(U,$J,358.3,8506,1,4,0)
;;=4^C92.60
;;^UTILITY(U,$J,358.3,8506,2)
;;=^5001807
;;^UTILITY(U,$J,358.3,8507,0)
;;=C92.A1^^39^401^11
;;^UTILITY(U,$J,358.3,8507,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8507,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
;;^UTILITY(U,$J,358.3,8507,1,4,0)
;;=4^C92.A1
;;^UTILITY(U,$J,358.3,8507,2)
;;=^5001814
;;^UTILITY(U,$J,358.3,8508,0)
;;=C92.A0^^39^401^12
;;^UTILITY(U,$J,358.3,8508,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8508,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
;;^UTILITY(U,$J,358.3,8508,1,4,0)
;;=4^C92.A0
;;^UTILITY(U,$J,358.3,8508,2)
;;=^5001813
;;^UTILITY(U,$J,358.3,8509,0)
;;=C92.51^^39^401^13
;;^UTILITY(U,$J,358.3,8509,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8509,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,8509,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,8509,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,8510,0)
;;=C92.50^^39^401^14
;;^UTILITY(U,$J,358.3,8510,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8510,1,3,0)
;;=3^Acute Myelomonocytic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,8510,1,4,0)
;;=4^C92.50
;;^UTILITY(U,$J,358.3,8510,2)
;;=^5001804
;;^UTILITY(U,$J,358.3,8511,0)
;;=C94.40^^39^401^17
;;^UTILITY(U,$J,358.3,8511,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8511,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
;;^UTILITY(U,$J,358.3,8511,1,4,0)
;;=4^C94.40
;;^UTILITY(U,$J,358.3,8511,2)
;;=^5001843
;;^UTILITY(U,$J,358.3,8512,0)
;;=C94.42^^39^401^15
;;^UTILITY(U,$J,358.3,8512,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8512,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
;;^UTILITY(U,$J,358.3,8512,1,4,0)
;;=4^C94.42
;;^UTILITY(U,$J,358.3,8512,2)
;;=^5001845
;;^UTILITY(U,$J,358.3,8513,0)
;;=C94.41^^39^401^16
;;^UTILITY(U,$J,358.3,8513,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8513,1,3,0)
;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
;;^UTILITY(U,$J,358.3,8513,1,4,0)
;;=4^C94.41
;;^UTILITY(U,$J,358.3,8513,2)
;;=^5001844
;;^UTILITY(U,$J,358.3,8514,0)
;;=D62.^^39^401^18
;;^UTILITY(U,$J,358.3,8514,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8514,1,3,0)
;;=3^Acute Posthemorrhagic Anemia
;;^UTILITY(U,$J,358.3,8514,1,4,0)
;;=4^D62.
;;^UTILITY(U,$J,358.3,8514,2)
;;=^267986
;;^UTILITY(U,$J,358.3,8515,0)
;;=C92.41^^39^401^19
;;^UTILITY(U,$J,358.3,8515,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8515,1,3,0)
;;=3^Acute Promyelocytic Leukemia,In Remission
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0IW 3753 printed Sep 23, 2025@19:25:33 Page 2
IBDEI0IW ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8503,2)
+2 ;;=^5001790
+3 ;;^UTILITY(U,$J,358.3,8504,0)
+4 ;;=C92.00^^39^401^8
+5 ;;^UTILITY(U,$J,358.3,8504,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,8504,1,3,0)
+8 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
+9 ;;^UTILITY(U,$J,358.3,8504,1,4,0)
+10 ;;=4^C92.00
+11 ;;^UTILITY(U,$J,358.3,8504,2)
+12 ;;=^5001789
+13 ;;^UTILITY(U,$J,358.3,8505,0)
+14 ;;=C92.61^^39^401^9
+15 ;;^UTILITY(U,$J,358.3,8505,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,8505,1,3,0)
+18 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
+19 ;;^UTILITY(U,$J,358.3,8505,1,4,0)
+20 ;;=4^C92.61
+21 ;;^UTILITY(U,$J,358.3,8505,2)
+22 ;;=^5001808
+23 ;;^UTILITY(U,$J,358.3,8506,0)
+24 ;;=C92.60^^39^401^10
+25 ;;^UTILITY(U,$J,358.3,8506,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,8506,1,3,0)
+28 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
+29 ;;^UTILITY(U,$J,358.3,8506,1,4,0)
+30 ;;=4^C92.60
+31 ;;^UTILITY(U,$J,358.3,8506,2)
+32 ;;=^5001807
+33 ;;^UTILITY(U,$J,358.3,8507,0)
+34 ;;=C92.A1^^39^401^11
+35 ;;^UTILITY(U,$J,358.3,8507,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,8507,1,3,0)
+38 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
+39 ;;^UTILITY(U,$J,358.3,8507,1,4,0)
+40 ;;=4^C92.A1
+41 ;;^UTILITY(U,$J,358.3,8507,2)
+42 ;;=^5001814
+43 ;;^UTILITY(U,$J,358.3,8508,0)
+44 ;;=C92.A0^^39^401^12
+45 ;;^UTILITY(U,$J,358.3,8508,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,8508,1,3,0)
+48 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
+49 ;;^UTILITY(U,$J,358.3,8508,1,4,0)
+50 ;;=4^C92.A0
+51 ;;^UTILITY(U,$J,358.3,8508,2)
+52 ;;=^5001813
+53 ;;^UTILITY(U,$J,358.3,8509,0)
+54 ;;=C92.51^^39^401^13
+55 ;;^UTILITY(U,$J,358.3,8509,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,8509,1,3,0)
+58 ;;=3^Acute Myelomonocytic Leukemia,In Remission
+59 ;;^UTILITY(U,$J,358.3,8509,1,4,0)
+60 ;;=4^C92.51
+61 ;;^UTILITY(U,$J,358.3,8509,2)
+62 ;;=^5001805
+63 ;;^UTILITY(U,$J,358.3,8510,0)
+64 ;;=C92.50^^39^401^14
+65 ;;^UTILITY(U,$J,358.3,8510,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,8510,1,3,0)
+68 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
+69 ;;^UTILITY(U,$J,358.3,8510,1,4,0)
+70 ;;=4^C92.50
+71 ;;^UTILITY(U,$J,358.3,8510,2)
+72 ;;=^5001804
+73 ;;^UTILITY(U,$J,358.3,8511,0)
+74 ;;=C94.40^^39^401^17
+75 ;;^UTILITY(U,$J,358.3,8511,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,8511,1,3,0)
+78 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
+79 ;;^UTILITY(U,$J,358.3,8511,1,4,0)
+80 ;;=4^C94.40
+81 ;;^UTILITY(U,$J,358.3,8511,2)
+82 ;;=^5001843
+83 ;;^UTILITY(U,$J,358.3,8512,0)
+84 ;;=C94.42^^39^401^15
+85 ;;^UTILITY(U,$J,358.3,8512,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,8512,1,3,0)
+88 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
+89 ;;^UTILITY(U,$J,358.3,8512,1,4,0)
+90 ;;=4^C94.42
+91 ;;^UTILITY(U,$J,358.3,8512,2)
+92 ;;=^5001845
+93 ;;^UTILITY(U,$J,358.3,8513,0)
+94 ;;=C94.41^^39^401^16
+95 ;;^UTILITY(U,$J,358.3,8513,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,8513,1,3,0)
+98 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
+99 ;;^UTILITY(U,$J,358.3,8513,1,4,0)
+100 ;;=4^C94.41
+101 ;;^UTILITY(U,$J,358.3,8513,2)
+102 ;;=^5001844
+103 ;;^UTILITY(U,$J,358.3,8514,0)
+104 ;;=D62.^^39^401^18
+105 ;;^UTILITY(U,$J,358.3,8514,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,8514,1,3,0)
+108 ;;=3^Acute Posthemorrhagic Anemia
+109 ;;^UTILITY(U,$J,358.3,8514,1,4,0)
+110 ;;=4^D62.
+111 ;;^UTILITY(U,$J,358.3,8514,2)
+112 ;;=^267986
+113 ;;^UTILITY(U,$J,358.3,8515,0)
+114 ;;=C92.41^^39^401^19
+115 ;;^UTILITY(U,$J,358.3,8515,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,8515,1,3,0)
+118 ;;=3^Acute Promyelocytic Leukemia,In Remission
